Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Barclays analyst Gena Wang downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight with a price target of $18.00 (from $32.00).

The analyst comments: "In the past few days, both SRPT and the FDA had escalated actions when dealing with the 3rd patient death across SRPT's AAVrh74 platform. SRPT's choice to selectively not disclose the 3rd patient death to the public drew a public outcry among investors. The ensuing FDA drastic change in course of action was equally disconcerting. We hosted a call with the same FDA policy KOL (see SRPT note, 07/14/2025) to gain the latest thoughts on Elevidys path forward. With the latest SRPT update this evening announcing in-comply with FDA request of drug delivery suspension, our KOL expected ~60-70% of prob of Elevidys returning to the market after temporary suspension. In the scenario of SRPT's non-comply, our KOL expected ~90% prob of HHS Secretary involvement later this week with a declaration of imminent safety concern under public health, entering uncharted territory. While we remain hopeful for opportunity in ambulatory pts, we have decided to step to the sideline until regulatory clarity is in place. Downgrade to EW and lower PT to $18."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $13.32 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades Holley (HLLY) to Hold
• Brinker Int'l (EAT) PT Raised to $230 at BMO Capital
• Trimble Navigation (TRMB) PT Lowered to $73 at Bernstein SocGen Group